Acceleron Pharma (XLRN) Rating Reiterated by Oppenheimer

Acceleron Pharma (NASDAQ:XLRN)‘s stock had its “hold” rating reiterated by equities research analysts at Oppenheimer in a research note issued on Tuesday, November 14th.

A number of other brokerages have also issued reports on XLRN. Piper Jaffray Companies reiterated a “buy” rating and set a $40.00 target price on shares of Acceleron Pharma in a research report on Friday, July 28th. Royal Bank Of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Thursday, November 2nd. BidaskClub upgraded Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a report on Sunday, August 6th. HC Wainwright started coverage on Acceleron Pharma in a report on Thursday, October 12th. They issued a “buy” rating and a $57.00 price objective on the stock. Finally, Credit Suisse Group set a $51.00 price objective on Acceleron Pharma and gave the company a “buy” rating in a report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Acceleron Pharma has a consensus rating of “Buy” and a consensus target price of $44.56.

Acceleron Pharma (XLRN) traded down $0.95 on Tuesday, hitting $35.54. 239,760 shares of the stock traded hands, compared to its average volume of 237,171. Acceleron Pharma has a 12-month low of $23.07 and a 12-month high of $40.35.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. During the same quarter in the prior year, the company earned ($0.55) EPS. Acceleron Pharma’s quarterly revenue was up .0% on a year-over-year basis. sell-side analysts forecast that Acceleron Pharma will post -2.67 EPS for the current year.

In related news, major shareholder Corp /De/ Celgene bought 745,592 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were acquired at an average price of $37.00 per share, with a total value of $27,586,904.00. Following the completion of the acquisition, the insider now owns 6,118,479 shares in the company, valued at approximately $226,383,723. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Kevin F. Mclaughlin sold 16,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $38.41, for a total value of $614,560.00. Following the completion of the transaction, the chief financial officer now directly owns 50,810 shares in the company, valued at approximately $1,951,612.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 53,513 shares of company stock worth $2,055,485. 3.90% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parametric Portfolio Associates LLC boosted its position in Acceleron Pharma by 3.9% during the second quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 355 shares in the last quarter. TD Asset Management Inc. boosted its position in Acceleron Pharma by 0.8% during the second quarter. TD Asset Management Inc. now owns 78,800 shares of the biopharmaceutical company’s stock worth $2,395,000 after purchasing an additional 600 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in Acceleron Pharma by 8.5% during the first quarter. Tudor Investment Corp ET AL now owns 9,105 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 716 shares in the last quarter. Legal & General Group Plc boosted its position in Acceleron Pharma by 9.7% during the second quarter. Legal & General Group Plc now owns 10,470 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 923 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in Acceleron Pharma by 2.1% during the first quarter. Teachers Advisors LLC now owns 46,080 shares of the biopharmaceutical company’s stock worth $1,220,000 after purchasing an additional 942 shares in the last quarter. Institutional investors own 85.73% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally published by BBNS and is owned by of BBNS. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://baseballnewssource.com/markets/acceleron-pharma-inc-xlrn-given-hold-rating-at-oppenheimer-holdings-inc/1782766.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.